US Patent 7,148,207: Fludarabine Phosphate Tablet Claims, Scope, Expiration and Generic-Entry Risk

US Patent 7,148,207 is directed to a specific quick-release oral tablet containing high-purity fludarabine phosphate, defined excipients, impurity limits, and optional film-coating components. The independent formulation claim is narrow because a competing product must satisfy every compositional, purity, impurity, and release limitation. The patent does not broadly cover fludarabine phosphate, all fludarabine dosage forms, injectable formulations, or every oral tablet.

The principal commercial issue is whether the patent remains enforceable. Its nominal term is governed by the earliest effective nonprovisional filing date, not its December 2006 issue date. A definitive expiration and current enforceability determination requires the USPTO continuity, patent-term-adjustment, maintenance-fee, and terminal-disclaimer records. Patent claims alone do not establish Orange Book listing status or current litigation exposure. [1-3]

What does US Patent 7,148,207 cover?

The patent covers a quick-release fludarabine phosphate tablet with five central elements:

Fludarabine phosphate at a specified dose and purity.
Lactose monohydrate.
Colloidal silicon dioxide.
Microcrystalline cellulose.
Sodium carboxymethyl cellulose and magnesium stearate.
A quick-release dissolution profile.
Maximum levels for 11 identified fludarabine-related impurities.

Claim 1 is the principal independent formulation claim. Claim 12 separately defines a cancer-treatment medication comprising the formulation of claim 1.

The claim is therefore a formulation-plus-quality-attribute claim. It is not limited solely by the identity of the active ingredient or by a particular tablet strength.

What product characteristics are required?

Claim element	Requirement in claim 1	Commercial significance
Dosage	1-100 mg fludarabine phosphate	Covers a wide dosage range
Active ingredient	Purity greater than 99.19%	Requires analytical qualification
Excipients	Lactose, colloidal silicon dioxide, microcrystalline cellulose, sodium carboxymethyl cellulose, magnesium stearate	Narrows formulation scope
Release	Quick-release profile	Requires dissolution or release testing
Impurity control	Individual limits for 11 named impurities	Creates potential API-source and manufacturing barriers
Dosage form	Tablet	Does not directly cover injection, capsule, solution, or suspension
Therapeutic use	Cancer treatment in claim 12	Method/use limitation layered onto the formulation

The claimed purity threshold is separate from the individual impurity limits. A product may have total active-ingredient purity above 99.19% but still fall outside the claim if one listed impurity exceeds its specified ceiling.

How do the dependent claims narrow the patent scope?

Claims 2 through 11 narrow claim 1 by adding quantitative formulation, purity, and coating limitations. They do not broaden the independent claim.

What formulations are protected by claims 2 through 4?

Claim	Fludarabine phosphate	Lactose	Colloidal silicon dioxide	Microcrystalline cellulose	Sodium carboxymethyl cellulose	Magnesium stearate
2	1-70 mg	50-100 mg	0.1-5 mg	40-100 mg	1-10 mg	0.5-10 mg
3	1-50 mg	60-90 mg	0.5-1 mg	50-90 mg	2.5-5 mg	1-3 mg
4	10 mg	74.75 mg	0.75 mg	60 mg	3 mg	1.5-2 mg

Claim 4 is the most commercially concrete core formulation. A 10 mg tablet using those excipients and quantities presents the highest literal-overlap risk among the stated claims, subject to the purity, impurity, and quick-release limitations.

The use of ranges creates a numerical claim-construction issue. A product may infringe claim 2 even if it falls outside claim 3, because claim 2 has broader excipient ranges. Claim 4 is narrower than claims 2 and 3 but provides a specific formulation target.

How do claims 5 through 8 protect API purity?

Claim	Minimum fludarabine phosphate purity
5	Greater than 99.37%
6	Greater than 99.57%
7	Greater than 99.80%
8	Greater than 99.85%

These claims create progressively narrower purity tiers. They are composition claims, not merely manufacturing-process claims. A generic manufacturer using a highly purified API could satisfy a higher-purity dependent claim even if its finished tablet differs from the precise formulation in claim 4.

The purity language raises analytical issues:

The testing method must define what counts as fludarabine phosphate and what counts as an impurity.
The claim does not state an analytical method in the text supplied.
Batch-to-batch variation may affect whether a product satisfies the thresholds.
Certificates of analysis, stability data, chromatograms, and API specifications would be central evidence in litigation.

What impurity limits are required?

Claim 1 identifies maximum concentrations for 11 named impurities or impurity groups. The limits range from 0.02% to 0.12%.

Impurity category	Maximum claimed level
2-fluoro-9-(β-D-arabinofuranosyl)-9H-purine-6-amine	0.02%
6-amino-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-2-ol	0.12%
2-fluoro-9H-purine-6-amine	0.02%
6-amino-9H-purin-2-ol	0.02%
Ribofuranosyl phosphonate analog	0.05%
Diphosphate arabinofuranosyl analogs	0.10% each
Arabinofuranosyl phosphonate analog	0.02%
2-ethoxy analog	0.06%
Dimeric purine phosphate impurity	0.02%
2-chloro deoxy analog	0.10%
2,5-anhydro analog	0.10%

These limits can create a practical barrier even when the formulation itself is easy to reproduce. A manufacturer may need a different synthetic route, crystallization protocol, purification step, or supplier to achieve the claimed profile.

What is the scope of the quick-release limitation?

"Quick release" is a functional limitation. Its enforceability depends on how the patent specification defines dissolution testing, apparatus, medium, agitation, sampling points, and acceptance criteria.

A conventional immediate-release fludarabine tablet could present literal-overlap risk if the specification's test conditions classify it as quick release. The term should not automatically be equated with every tablet that is not extended release. The relevant question is whether the accused product satisfies the patent's disclosed release test or the legally applicable construction of the term.

A generic applicant would normally evaluate:

dissolution profile;
tablet disintegration;
coating effect;
compression force;
particle size;
excipient grade;
storage stability; and
whether release depends on a formulation feature outside the claimed composition.

What coating formulations are protected?

Claims 9 through 11 cover a tablet core encased by a coating containing hydroxypropyl methyl cellulose, talc, titanium dioxide, yellow iron oxide, and red iron oxide.

Claim	HPMC	Talc	Titanium dioxide	Yellow iron oxide	Red iron oxide
9	1-5 mg	0.1-1 mg	0.1-5 mg	0.01-0.1 mg	0.01-0.1 mg
10	1-3 mg	0.1-0.8 mg	0.1-2 mg	0.01-0.05 mg	0.01-0.05 mg
11	2.250 mg	0.450 mg	1.187 mg	0.036 mg	0.036 mg

Claim 11 is a narrow coating formulation. It depends on claim 1, so the core tablet must also satisfy the active-ingredient, excipient, release, and impurity requirements.

A color or coating redesign may reduce literal infringement risk under claims 9-11, but it would not avoid claims 1-8 if the underlying core remains within those claims.

Does US Patent 7,148,207 cover fludarabine injection?

No direct coverage follows from the supplied claims. The claims require a tablet or a medication comprising that tablet formulation. A conventional injectable fludarabine phosphate product would generally fall outside the literal scope because it lacks the claimed tablet, excipient system, and coating.

The patent also does not, on the supplied claims, cover:

fludarabine phosphate API by itself;
manufacturing methods for fludarabine phosphate;
intravenous solutions;
oral liquids;
capsules;
liposomal fludarabine;
extended-release tablets; or
treatment methods that do not use the claimed tablet.

When does US Patent 7,148,207 lose exclusivity?

US patent term generally runs for 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments. The issue date of December 12, 2006 does not establish the expiration date. [2]

For a reliable expiration analysis, the relevant record is:

Term issue	Relevance
Earliest nonprovisional priority	Establishes the baseline 20-year term
Continuation or divisional status	Can affect the effective filing date
Patent-term adjustment	May add days for USPTO delay
Patent-term extension	Potentially relevant for qualifying regulatory review
Terminal disclaimer	Can shorten the term
Maintenance fees	Nonpayment can cause expiration before the nominal term
Reexamination or post-grant proceedings	May cancel or amend claims

A patent can be technically unexpired but commercially irrelevant if its claims are not listed for the relevant FDA product, if all enforceable claims were canceled, or if the marketed product does not practice the claims.

What is the Orange Book status of US Patent 7,148,207?

The patent number alone does not establish Orange Book listing. FDA Orange Book listings are tied to a specific approved drug product, applicant, dosage form, route, and regulatory submission. FDA regulations require drug sponsors to identify patents that claim the drug substance, drug product, or an approved method of use, subject to the applicable statutory and regulatory framework. [3]

For fludarabine phosphate, the relevant regulatory questions are:

Was the patent listed against an approved oral tablet application?
Was it listed against the injectable product?
Did the listing remain active during the relevant ANDA filing period?
Did the listing contain a drug-product or method-of-use patent suitable for certification?
Was the patent delisted, expired, or removed?

The supplied claim text indicates a drug-product formulation patent rather than a drug-substance patent. It would therefore have the strongest Orange Book relevance to an oral tablet product matching the claimed formulation, not to an injectable formulation.

How would a Paragraph IV challenge apply?

A generic applicant seeking approval for a tablet product may address an Orange Book patent through a Paragraph IV certification if it asserts that the patent is invalid, unenforceable, or will not be infringed. The ANDA process and 30-month litigation stay are governed by the Hatch-Waxman framework. [4]

Potential Paragraph IV positions include:

Noninfringement

A generic could argue that it lacks one or more required elements, such as:

a listed excipient;
the claimed quantity range;
one or more named impurity thresholds;
the claimed purity level;
the quick-release profile; or
the claimed coating composition.

Because claim 1 is conjunctive, omission of one required excipient or failure to meet one impurity limitation can defeat literal infringement.

Invalidity for anticipation

Prior art could anticipate the claim if a single reference disclosed the complete combination, including:

the specified fludarabine phosphate purity;
the named impurity limits;
the exact excipient combination;
the tablet dosage range; and
the quick-release profile.

A reference disclosing fludarabine tablets generally would not necessarily anticipate the claim if it did not disclose the impurity profile or purity threshold.

Invalidity for obviousness

The most likely obviousness theory would combine known fludarabine tablet formulations with known high-purity API specifications and routine immediate-release excipient systems. The patent holder would likely rely on the impurity limits, release behavior, and formulation performance as evidence of a non-routine result. The strength of that defense would depend on the patent's examples, comparative data, prosecution history, and prior-art disclosure.

Written description and enablement

A challenge could examine whether the specification supports the full 1-100 mg dose range, all listed impurity combinations, all excipient ranges, and the functional quick-release limitation. Broad genus claims supported only by a small number of examples can create written-description and enablement issues under 35 U.S.C. §112. [5]

Which companies are challenging the patent?

No challenger, ANDA filer, Paragraph IV notice, litigation case, or settlement agreement can be identified from the claim text alone. A reliable company-by-company challenge analysis requires matching the patent to:

FDA Orange Book records;
FDA ANDA approvals;
Paragraph IV notices;
district-court complaints;
Federal Circuit decisions;
Abbreviated New Drug Application litigation databases; and
commercial product labels.

The patent number should not be treated as evidence that a particular generic manufacturer challenged it.

How strong is the patent estate for fludarabine phosphate?

The supplied claims indicate a narrow but potentially useful formulation estate.

Dimension	Assessment
Active-ingredient coverage	Narrow; limited to high-purity fludarabine phosphate in a tablet
Excipient coverage	Moderate; claim 1 requires a specific five-excipient system
Impurity control	Potentially strong if the limits are difficult to achieve and well supported
Dosage coverage	Broad in claim 1, narrower in claims 2-4
Coating coverage	Narrow and readily design-aroundable
Method-of-use coverage	Limited to the medication claim supplied; no detailed cancer indication appears in claim 12
Injectable coverage	None apparent from the supplied claims
Manufacturing coverage	None apparent from the supplied claims
Biosimilar protection	Not applicable to this small-molecule formulation patent
Generic vulnerability	Meaningful because alternative excipients, coatings, impurity profiles, or release characteristics may avoid literal infringement

The most defensible commercial value would be a 10 mg oral tablet manufactured with the specified excipient system and impurity controls. The weakest portion is the coating sub-claim set because colorants, coating weights, and coating polymers can often be changed without altering therapeutic performance.

What generic launch scenarios exist?

Launch after patent expiry

This is the lowest-risk pathway if the patent has expired and no related unexpired patent remains listed or enforceable.

Paragraph III certification

An ANDA applicant may acknowledge the patent and defer approval until the patent expires. This avoids a Paragraph IV litigation trigger but delays launch.

Paragraph IV certification

The applicant may challenge validity, enforceability, or infringement. The principal noninfringement strategy would be a formulation design-around supported by analytical data.

Non-infringing formulation

A generic could attempt to use:

a different filler;
a different glidant;
a different disintegrant;
a different lubricant;
a different coating system;
a different impurity profile; or
a release profile outside the patent's construction of quick release.

Such a product would still require FDA approval and must satisfy bioequivalence and pharmaceutical-quality requirements. FDA's ANDA pathway generally focuses on pharmaceutical equivalence, bioequivalence, active-ingredient quality, manufacturing controls, and labeling requirements. [6]

Does biosimilar risk apply?

No. Fludarabine phosphate is a small-molecule active ingredient. Competing products would ordinarily proceed through the generic drug pathway, not the biosimilar pathway under the Public Health Service Act. The relevant competitive risks are ANDA approval, authorized generic supply, formulation design-around, API sourcing, and possible Paragraph IV litigation.

Key Takeaways

US Patent 7,148,207 claims a specific quick-release fludarabine phosphate tablet, not fludarabine broadly.
Claim 1 requires the active ingredient, five named excipients, quick release, high purity, and limits for 11 impurities.
Claims 2-4 narrow the formulation quantities; claim 4 targets a 10 mg tablet.
Claims 5-8 protect progressively higher purity thresholds, reaching greater than 99.85%.
Claims 9-11 protect specific film-coating compositions.
Claim 12 is a cancer-treatment medication claim dependent on the formulation of claim 1.
The claims supplied do not directly cover injectable fludarabine, API manufacture, capsules, oral liquids, or extended-release products.
The patent number alone does not establish current enforceability, Orange Book status, litigation status, or a Paragraph IV challenge.
Generic risk is highest for a product reproducing the claimed core formulation and impurity profile.
A formulation design-around may avoid literal infringement if it changes a required excipient, coating, impurity threshold, or release characteristic.
Biosimilar analysis is not relevant; the competitive pathway is generic drug approval.

Frequently Asked Questions

Is fludarabine phosphate protected by a composition-of-matter patent?

The supplied claims do not claim fludarabine phosphate as a standalone chemical compound. They claim a tablet formulation containing high-purity fludarabine phosphate and specified excipients.

Does using 10 mg fludarabine automatically infringe claim 4?

No. The product must also satisfy the specified excipient quantities, purity, impurity limits, tablet structure, and quick-release limitation.

Can a generic avoid the patent by changing only the tablet color?

Changing the color may avoid a coating claim such as claim 11, but it would not avoid claims 1-8 if the core formulation remains within those claims.

Does a different fludarabine API supplier avoid infringement?

Not necessarily. Supplier identity is not a claim limitation. The relevant issue is whether the API meets the claimed purity and individual impurity limits.

Is a fludarabine injection a direct alternative to the claimed patent?

From the supplied claims, yes, in the patent-scope sense. An injectable product does not contain the claimed tablet formulation, tablet excipients, or claimed coating. Its regulatory and clinical substitutability would be a separate issue.

References

United States Patent No. 7,148,207, claims 1-12. United States Patent and Trademark Office.
35 U.S.C. § 154. Patent term.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
21 U.S.C. § 355(j); 35 U.S.C. § 271(e). Abbreviated new drug applications and patent-related litigation.
35 U.S.C. § 112. Specification requirements.
U.S. Food and Drug Administration. (2015). ANDA submissions: Content and format guidance for industry.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	101 64 510	Dec 20, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037965	⤷ Start Trial
Austria	303797	⤷ Start Trial
Australia	2002349043	⤷ Start Trial
Brazil	0215265	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,148,207

Summary for Patent: 7,148,207